{"title":"对“b细胞成熟抗原治疗复发或难治性多发性骨髓瘤”的修正","authors":"","doi":"10.1002/jha2.70056","DOIUrl":null,"url":null,"abstract":"<p>Shrestha A, Alzubi M, Alrawabdeh J, Schinke C, Thanendrarajan S, Zangari M, et al. B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma. eJHaem. 2024;5:554-59. doi:10.1002/jha2.896</p><p>Carolina Schinke has mistakenly not declared her Conflict of Interest and would like to add a sentence stating “CS has participated in Advisory Board Meetings of Janssen, Pfizer and Arcellx”.</p><p>We apologize for this error.</p>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70056","citationCount":"0","resultStr":"{\"title\":\"Correction to “B-cell Maturation Antigen-Based Therapies Post-Talquetamab in Relapsed or Refractory Multiple Myeloma”\",\"authors\":\"\",\"doi\":\"10.1002/jha2.70056\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Shrestha A, Alzubi M, Alrawabdeh J, Schinke C, Thanendrarajan S, Zangari M, et al. B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma. eJHaem. 2024;5:554-59. doi:10.1002/jha2.896</p><p>Carolina Schinke has mistakenly not declared her Conflict of Interest and would like to add a sentence stating “CS has participated in Advisory Board Meetings of Janssen, Pfizer and Arcellx”.</p><p>We apologize for this error.</p>\",\"PeriodicalId\":72883,\"journal\":{\"name\":\"EJHaem\",\"volume\":\"6 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70056\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJHaem\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70056\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70056","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
Shrestha A, Alzubi M, Alrawabdeh J, Schinke C, Thanendrarajan S, Zangari M，等。b细胞成熟抗原治疗复发或难治性多发性骨髓瘤。eJHaem。2024; 5:554-59。carolina Schinke错误地没有声明她的利益冲突，并希望添加一句“CS参加了Janssen， Pfizer和Arcellx的顾问委员会会议”。我们为这个错误道歉。
Correction to “B-cell Maturation Antigen-Based Therapies Post-Talquetamab in Relapsed or Refractory Multiple Myeloma”
Shrestha A, Alzubi M, Alrawabdeh J, Schinke C, Thanendrarajan S, Zangari M, et al. B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma. eJHaem. 2024;5:554-59. doi:10.1002/jha2.896
Carolina Schinke has mistakenly not declared her Conflict of Interest and would like to add a sentence stating “CS has participated in Advisory Board Meetings of Janssen, Pfizer and Arcellx”.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
